Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.25 and traded as low as $2.93. Galmed Pharmaceuticals shares last traded at $2.99, with a volume of 35,615 shares.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a research report on Wednesday, October 9th. They set a “sell” rating on the stock.

Galmed Pharmaceuticals Trading Down 5.5 %

The company has a 50-day moving average price of $4.73 and a 200 day moving average price of $4.23. The stock has a market capitalization of $1.88 million, a P/E ratio of -0.17 and a beta of 0.80.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share for the quarter.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.